Genfit S.A./€GNFT
1D1W1MYTD1Y5YMAX
Capital at risk
About Genfit S.A.
Genfit S.A. is a French biopharmaceutical company focused on developing therapeutics and diagnostic solutions for metabolic and liver-related diseases. Known for its work in treating nonalcoholic steatohepatitis (NASH) and other liver diseases, Genfit offers key products including investigational drugs such as elafibranor and diagnostic tests like NIS4 for identifying NASH. Founded in 1999, the company is headquartered in Loos, France. Its strategic positioning lies in addressing unmet medical needs in liver health, supported by a robust research and development pipeline. Genfit's competitive strengths include expertise in nuclear receptor pathways and strategic partnerships with other biopharmaceutical firms.
- Ticker
- €GNFT
- Sector
- Health
- Primary listing
- PAR
- Employees
- 161
- Headquarters
- Loos, France
- Website
- www.genfit.com
Genfit S.A. Metrics
BasicAdvanced
€624M
-
-€1.72
1.14
-
Price and volume
Market cap
€624M
Beta
1.14
52-week high
€15.40
52-week low
€3.30
Average daily volume
257K
Financial strength
Current ratio
1.995
Quick ratio
1.956
Long term debt to equity
-4.783
Total debt to equity
-6.687
Interest coverage (TTM)
-10.25%
Profitability
EBITDA (TTM)
-51.737
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-121.35%
Operating margin (TTM)
-81.86%
Effective tax rate (TTM)
0.61%
Revenue per employee (TTM)
€410,000
Management effectiveness
Return on assets (TTM)
-21.59%
Return on equity (TTM)
-368.27%
Valuation
Price to revenue (TTM)
8.795
Price to book
-27.79
Price to tangible book (TTM)
-23.39
Price to free cash flow (TTM)
-21.063
Free cash flow yield (TTM)
-4.75%
Free cash flow per share (TTM)
-0.593
Growth
Revenue change (TTM)
0.22%
Earnings per share change (TTM)
-5,833.33%
3-year revenue growth (CAGR)
35.60%
10-year revenue growth (CAGR)
31.46%
3-year earnings per share growth (CAGR)
53.16%
10-year earnings per share growth (CAGR)
9.20%
Bulls say / Bears say
Iqirvo® is generating a growing royalty stream through Ipsen: 2025 sales exceeded US$200 million, triggering a US$20 million milestone, while Q1 2026 Iqirvo® net sales reached €78.8 million. (GENFIT)
NASHnext®, powered by GENFIT’s NIS4® technology, gained U.S. Medicare coverage effective August 10, 2026, with reimbursement of approximately $252 per test, creating a potential second revenue stream alongside Iqirvo® royalties. (GENFIT)
GNS561 produced positive Phase 1b combination data in heavily pretreated KRAS-mutated cholangiocarcinoma, showing favorable safety and early signs of antitumor activity, with Phase 2 initiation targeted for the second half of 2026. (GENFIT)
GENFIT’s clinical pipeline remains high risk: its CCA, ACLF and PSC programs are still in Phase 1/2 or partner-led development, with efficacy, safety and regulatory outcomes unresolved. (GENFIT)
NASHnext® has secured Medicare coverage, but commercial uptake and recurring economics remain unproven; GENFIT itself identifies payer adoption, rollout and revenue generation as forward-looking uncertainties. (GENFIT)
Reported revenue remains exposed to partner performance and milestone timing: Q1 2026 revenue was only €9.6 million and came from Iqirvo® royalties, while prior-year results were materially supported by milestone payments rather than a broad, diversified product base. (GENFIT)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.